论文部分内容阅读
Trilostane是一种3β-羟类固醇脱氢酶系统的竞争抑制剂,已证实对鼠、狗和豚鼠有肾上腺阻滞作用。本文报告用trilostane治疗6例柯兴氏综合征病人。6例患者均由临床和生化证据所确诊,其中4例有高血压,除1例有轻度糖尿病外,其余5例血钾和血糖均正常。 Trilostane开始剂量为240mg/d,如果对该药无临床或生化反应,则于3天或更长时间后增加剂量。6例中剂量最小的1例是480mg/d,剂量最大的1例是1,440mg/d。在开始用药前和达到最大剂量时各连续2次用荧光法和放射免疫法测定激素值。
Trilostane is a competitive inhibitor of the 3-hydroxysteroid dehydrogenase system and has been shown to block adrenal arrest in rats, dogs and guinea pigs. This article reports the use of trilostane in treating 6 patients with Cushing’s syndrome. Six patients were diagnosed by clinical and biochemical evidence, of which four had hypertension and one had mild diabetes, while the other five had normal serum and blood glucose levels. The starting dose of Trilostane is 240 mg / d, and if there is no clinical or biochemical reaction to the drug, the dose is increased after 3 days or more. One of the 6 cases with the lowest dose was 480 mg / day and the other 1 case with the highest dose was 1,440 mg / day. The hormone values were determined by fluorescence and radioimmunoassay two consecutive times prior to the start of administration and at the maximum dose.